Abstract | GOALS OF WORK: METHODS: An economic model was developed based on data from phase III megestrol-controlled clinical trials of antiaromatase agents (AA) and estimates of resource utilization from both Statistic Canada's Population Health Model for breast cancer and expert opinion. MAIN RESULTS: In megestrol-controlled trials, anastrozole and exemestane equivalently improved survival compared to megestrol, while letrozole did not. Compared to megestrol, exemestane and anastrozole both cost Canadian $9000 per life-year gained, and letrozole saved Canadian $300 annually, with no life-year gain. Cost-effectiveness results were robust under sensitivity analysis testing. However, the model was dependent on any difference between AAs with respect to survival benefit and drug acquisition price. CONCLUSION: Based on available data and this cost-effectiveness analysis, exemestane and anastrozole are appropriate choices for second-line hormonal treatment of metastatic breast cancer.
|
Authors | Shailendra Verma, Angela Rocchi |
Journal | Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer
(Support Care Cancer)
Vol. 11
Issue 11
Pg. 728-34
(Nov 2003)
ISSN: 0941-4355 [Print] Germany |
PMID | 12883965
(Publication Type: Comparative Study, Evaluation Study, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Androstadienes
- Antineoplastic Agents
- Aromatase Inhibitors
- Enzyme Inhibitors
- Nitriles
- Triazoles
- Anastrozole
- Letrozole
- Megestrol
- exemestane
|
Topics |
- Aged
- Anastrozole
- Androstadienes
(economics, therapeutic use)
- Antineoplastic Agents
(economics, therapeutic use)
- Aromatase Inhibitors
- Breast Neoplasms
(drug therapy, economics, pathology)
- Canada
- Clinical Trials, Phase III as Topic
- Cost-Benefit Analysis
- Enzyme Inhibitors
(economics, therapeutic use)
- Female
- Humans
- Letrozole
- Megestrol
(economics, therapeutic use)
- Middle Aged
- Nitriles
(economics, therapeutic use)
- Quality-Adjusted Life Years
- Randomized Controlled Trials as Topic
- Survival Analysis
- Triazoles
(economics, therapeutic use)
|